San Francisco-based life sciences company Burrill has formed a partnership with Beijing Pharmaceutical Group (BPGC), one of the largest pharmaceutical and medical device companies in China, to develop and manufacture new pharmaceutical products.
"We're honored to add BPGC to our family of outstanding global strategic partners," said G. Steven Burrill, CEO of Burrill. "Burrill will provide its deep life sciences knowledge and experience, and global network and resources, to assist BPGC to become a leading player in the global pharmaceutical industry."
BPGC develops, manufactures and markets pharmaceuticals, biopharmaceuticals,
health products, pharmaceutical raw materials, intermediates, medical equipment
and medicine-manufacturing equipment.